Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Update

Kura Oncology, Inc. (NASDAQ:KURA) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 10,440,000 shares, an increase of 17.4% from the December 15th total of 8,890,000 shares. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is presently 6.3 days. Approximately 16.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. raised its stake in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the period. JPMorgan Chase & Co. raised its stake in Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after acquiring an additional 3,092 shares during the period. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. HighVista Strategies LLC bought a new position in shares of Kura Oncology in the second quarter worth approximately $345,000. Finally, Alethea Capital Management LLC increased its stake in shares of Kura Oncology by 2.4% in the second quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after purchasing an additional 6,300 shares in the last quarter.

Wall Street Analysts Forecast Growth

KURA has been the subject of a number of analyst reports. UBS Group assumed coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. HC Wainwright raised their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Performance

NASDAQ:KURA traded up $0.08 on Friday, hitting $7.26. The stock had a trading volume of 1,174,495 shares, compared to its average volume of 1,533,541. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $564.54 million, a price-to-earnings ratio of -3.08 and a beta of 0.81. The business’s 50-day simple moving average is $10.51 and its two-hundred day simple moving average is $16.36. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.